RT Journal Article
T1 Critically short telomeres and toxicity of chemotherapy in early breast cancer.
A1 Quintela-Fandino, Miguel
A1 Soberon, Nora
A1 Lluch, Ana
A1 Manso, Luis
A1 Calvo, Isabel
A1 Cortes, Javier
A1 Moreno-Antón, Fernando
A1 Gil-Gil, Miguel
A1 Martinez-Jánez, Noelia
A1 Gonzalez-Martin, Antonio
A1 Adrover, Encarna
A1 de Andres, Raquel
A1 Viñas, Gemma
A1 Llombart-Cussac, Antonio
A1 Alba, Emilio
A1 Mouron, Silvana
A1 Guerra, Juan
A1 Bermejo, Begoña
A1 Zamora, Esther
A1 García-Saenz, Jose Angel
A1 Simon, Sonia Pernas
A1 Carrasco, Eva
A1 Escudero, María José
A1 Campo, Ruth
A1 Colomer, Ramón
A1 Blasco, Maria A
K1 breast cancer
K1 critically short telomeres
K1 telomere length
K1 toxicity
K1 weekly paclitaxel
AB Cumulative toxicity from weekly paclitaxel (myalgia, peripheral neuropathy, fatigue) compromises long-term administration. Preclinical data suggest that the burden of critically short telomeres ( 21.9% CSTs) had 2-fold higher number of neuropathy (P = 0.04) or fatigue (P = 0.019) episodes and >3-fold higher number of myalgia episodes (P = 0.005). The average telomere length was unrelated to the incidence of side effects.The percentage of CSTs, but not the average telomere size, is associated with weekly paclitaxel-derived toxicity.
YR 2017
FD 2017
LK https://hdl.handle.net/10668/25129
UL https://hdl.handle.net/10668/25129
LA en
DS RISalud
RD Apr 4, 2025